If you have been reading about lipolysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-29. Numbers and descriptions here follow the published literature rather than marketing material.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
== Scientific investigations == Over the decades, many clinical studies have been performed to investigate TT's efficacy, as well as various meta-analyses and at least one systematic review, yielding varying results and conclusions. O'Mathúna et al., in discussing these studies, note several problems, such as failure to exclude methodologically flawed studies and a susceptibility to the publication bias of complementary medicine journals, which carry a "preponderance of studies with positive results"; they argue that
Monosaccharides are also called "simple sugars", the most important being glucose. Most monosaccharides have a formula that conforms to CnH2nOn with n between 3 and 7 (deoxyribose being an exception). Glucose has the molecular formula C6H12O6. The names of typical sugars end with -ose, as in "glucose" and "fructose". Such labels may also refer to any types of these compounds. Fructose, galactose and glucose are all simple sugars, monosaccharides, with the general formula C6H12O6. They have five hydroxyl groups (−OH) and a carbonyl group (C=O) and are cyclic when dissolved in water. They each exist as several isomers with dextro- and laevo-rotatory forms that cause polarised light to diverge to the right or the left.
== Example secreted proteins == α-Amylase (1A, 1B, 1C) – breaks down carbohydrates, especially starch. Histatin (HTN1, HTN3) – have a variety of roles from inhibiting fungus growth, acting as precursors for enamel, and promoting wound healing. Lactoperoxidase – reacts with thiocyanate ions to produce antimicrobial molecules. Lactoferrin – binds to iron which has antimicrobial effects. Proline rich proteins Basic (1, 2, 3, 4) Acidic (1, 2) Proline-rich protein 4 (PRR4) – Also produced by lacrimal acinar cells Statherin – helps stabilize saliva and prevent calcium precipitation.
== Locations == The company opened its first location on August 26, 2002, near the intersection of 21st Street and Tyler Road in Wichita; this location is still in operation. In November 2022, it was announced that Freddy's would be expanding to nine provinces in Canada, with the first location set for a 2025 opening. As of September 10, 2025, Freddy's had 560 locations across 37 states. Additionally, the chain opened in non-traditional locations such as OKC Will Rogers International Airport in Oklahoma City and Busch Stadium in St. Louis.
HLA-G histocompatibility antigen, class I, G, also known as human leukocyte antigen G (HLA-G), is a protein that in humans is encoded by the HLA-G gene. HLA-G belongs to the HLA nonclassical class I heavy chain paralogues. Classical HLA I proteins are found on all nucleated cells and express peptides in their peptide binding groove. They can express "self" peptides when the cell is healthy as well as foreign peptides when the cell is infected by a parasite or cancer. HLA-G is a nonclassical protein and serves a different function from classical HLA class I molecules, but it still expresses a nine amino acid peptide in its peptide binding groove. The third and ninth amino acid in the peptide sequence serve as anchor residues, and are thus conserved in all the peptides HLA-G bind to.
Sources: en.wikipedia.org
== Indications == DBNPA is used as a disinfectant, bactericide, algicide, slime remover, and mildew inhibitor in several industrial applications. It is frequently used to regulate the growth of bacteria, algae, and slime in oilfield water injection systems and circulating cooling water systems. DBNPA is used in the paper industry as a slime remover, bactericide, and algicide to keep machinery free of microorganisms and maintain product quality. Additionally, it is utilized as a preservative to prevent microbiological deterioration in paints, waxes, inks, detergents, surfactants, slurries, and resins. DBNPA also serves as a fungicide and algaecide in municipal water landscapes, guaranteeing water safety and clarity, and as a biocide in process water and air purifier systems in the machinery manufacturing sector. The concentration used when it is being used as a water treatment slime stripper is 30~50 mg/L. When it is being used for water treatment, as a bactericide, it is used at a concentration of 10~20 mg/L. In terms of analytical detection in industrial and environmental samples, high-performance liquid chromatography with UV detection, measuring absorption at 230 nm, detects DBNPA at extremely low concentrations (>0.1 mg/L) in water samples. Gas chromatography-mass spectrometry can also identify and quantify DBNPA and the associated degradation products, (detection limit is 0.05 mg/L) in environmental samples.
So the presence of effector genes within such regions is suggested to promote their adaptation and diversification when exposed to strong selection pressure. As RIP mutation is traditionally observed to be restricted to repetitive regions and not single copy regions, Fudal et al. suggested that leakage of RIP mutation might occur within a relatively short distance of a RIP-affected repeat. Indeed, this has been reported in N. crassa whereby leakage of RIP was detected in single copy sequences at least 930 bp from the boundary of neighbouring duplicated sequences. To elucidate the mechanism of detection of repeated sequences leading to RIP may allow to understand how the flanking sequences may also be affected.
A highly divisive figure, Gaddafi dominated Libya's politics for four decades and was the subject of a pervasive cult of personality. He was decorated with various awards and praised for his anti-imperialist stance, support for Arab—and then African—unity, as well as for significant development to the country after the discovery of oil reserves. Conversely, many Libyans strongly opposed Gaddafi's social and economic reforms; he was accused of various human rights violations. He was condemned by many as a dictator whose authoritarian administration systematically violated human rights and financed terrorism in the region and abroad.
Member Natl. Acad. Sci. USA. Yuri Ovchinnikov (1934–1988). Soviet biochemist at Moscow State University and the Protein Institute of the Academy of Sciences of the Soviet Union known for research on rhodopsin and structural biology. Full member of the Academy of Sciences of the Soviet Union.
==== Nibble ==== A measure of quantity of data or information, the "nibble" (sometimes spelled "nybble" or "nybl") is normally equal to 4 bits, or one half of the common 8-bit byte. The nibble is used to describe the amount of memory used to store a digit of a number stored in binary-coded decimal format, or to represent a single hexadecimal digit. Less commonly, 'nibble' may be used for any contiguous portion of a byte of specified length, e.g. "6-bit nibble"; this usage is most likely to be encountered in connection with a hardware architecture in which the word length is not a multiple of 8, such as older 36-bit minicomputers.
Sources: en.wikipedia.org
=== Psychological support === Psychological support, often in the form of cognitive-behavioral therapy (CBT), family-based treatment, or psychotherapy aims to change distorted thoughts and behaviors around food, body image, and self-worth, with family-based therapy also being a key approach for younger patients.
Boletus edulis was first described in 1782 by the French botanist Pierre Bulliard and still bears its original name. The starting date of fungal taxonomy had been set as January 1, 1821, to coincide with the date of the works of the 'father of mycology', Swedish naturalist Elias Magnus Fries, which meant the name required sanction by Fries (indicated in the name by a colon) to be considered valid, as Bulliard's work preceded this date. It was thus written Boletus edulis Bull.:Fr. A 1987 revision of the International Code of Botanical Nomenclature set the starting date at May 1, 1753, the date of publication of Carl Linnaeus' Species Plantarum. Hence, the name no longer requires the ratification of Fries' authority. Early alternate names include Boletus solidus by English naturalist James Sowerby in 1809, and Gray's Leccinum edule. Gray's transfer of the species to Leccinum was later determined to be inconsistent with the rules of botanical nomenclature, and he apparently was unfamiliar with the earlier works of Fries when he published his arrangement of bolete species. Boletus edulis is the type species of the genus Boletus.
=== Plasma synthesis === Plasma synthesis has evolved to be one of the most popular gas-phase approaches for the production of quantum dots, especially those with covalent bonds. For example, silicon and germanium quantum dots have been synthesized by using nonthermal plasma. The size, shape, surface and composition of quantum dots can all be controlled in nonthermal plasma. Doping that seems quite challenging for quantum dots has also been realized in plasma synthesis. Quantum dots synthesized by plasma are usually in the form of powder, for which surface modification may be carried out. This can lead to excellent dispersion of quantum dots in either organic solvents or water (i. e., colloidal quantum dots).
== Side effects == Like any form of radiotherapy, ionising radiation can harm healthy tissue as well as the intended treatment target. Radiation from lutetium (177Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney. Arginine/lysine can be used to reduce renal radiation exposure during peptide receptor radionuclide therapy with lutetium (177Lu) oxodotreotide.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.